Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Clinical and Experimental Medicine Pub Date : 2024-11-18 DOI:10.17219/acem/189914

Qing Zheng, Zhenqi Gong, Baizhi Li, Huaiming Wang, Shaoxiong Lin

{"title":"Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer.","authors":"Qing Zheng, Zhenqi Gong, Baizhi Li, Huaiming Wang, Shaoxiong Lin","doi":"10.17219/acem/189914","DOIUrl":null,"url":null,"abstract":"Background: Accumulating evidence has supported the effect of antibody-dependent cellular phagocytosis (ADCP) on the tumor microenvironment (TME) and cancer therapy. However, an ADCP-based signature to predict the prognosis of gastric cancer (GC) has not been established.Objectives: We aimed to develop an ADCP-based signature to improve the prognosis prediction of GC.Material and methods: Antibody-dependent cellular phagocytosis genes that exhibited a differential expression were characterized, followed by the construction and validation of the ADCP-based signature. The potential association between the ADCP-based signature and TME was explored, and the features of the signature genes were investigated. Finally, a predictive nomogram was established based on the ADCP-based signature.Results: Four ADCP-related genes, MKNK2, VCAN, LRAT, and GNGB, were identified to construct the ADCP-based signature, and a high ADCP score predicted an unfavorable prognosis in GC patients (p < 0.05). The ADCP-based signature was significantly associated with immune cells, immune checkpoints and immune signaling pathways (p < 0.05). Gastric cancer patients with high ADCP scores benefited less from immunotherapy compared to those with low ADCP scores. A nomogram including age, stage and risk score of the ADCP-based signature was constructed to predict the 1-, 3- and 5-year survival probabilities, with an area under the curve (AUC) of 0.669, 0.675 and 0.685, respectively.Conclusions: The ADCP-based signature may serve as a new option for prognosis prediction and the personalized treatment of GC patients.","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17219/acem/189914","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Accumulating evidence has supported the effect of antibody-dependent cellular phagocytosis (ADCP) on the tumor microenvironment (TME) and cancer therapy. However, an ADCP-based signature to predict the prognosis of gastric cancer (GC) has not been established.

Objectives: We aimed to develop an ADCP-based signature to improve the prognosis prediction of GC.

Material and methods: Antibody-dependent cellular phagocytosis genes that exhibited a differential expression were characterized, followed by the construction and validation of the ADCP-based signature. The potential association between the ADCP-based signature and TME was explored, and the features of the signature genes were investigated. Finally, a predictive nomogram was established based on the ADCP-based signature.

Results: Four ADCP-related genes, MKNK2, VCAN, LRAT, and GNGB, were identified to construct the ADCP-based signature, and a high ADCP score predicted an unfavorable prognosis in GC patients (p < 0.05). The ADCP-based signature was significantly associated with immune cells, immune checkpoints and immune signaling pathways (p < 0.05). Gastric cancer patients with high ADCP scores benefited less from immunotherapy compared to those with low ADCP scores. A nomogram including age, stage and risk score of the ADCP-based signature was constructed to predict the 1-, 3- and 5-year survival probabilities, with an area under the curve (AUC) of 0.669, 0.675 and 0.685, respectively.

Conclusions: The ADCP-based signature may serve as a new option for prognosis prediction and the personalized treatment of GC patients.

查看原文本刊更多论文

基于抗体依赖性细胞吞噬作用特征的开发与验证：胃癌预后风险模型

背景：越来越多的证据支持抗体依赖性细胞吞噬（ADCP）对肿瘤微环境（TME）和癌症治疗的影响。然而，基于 ADCP 的胃癌预后预测特征尚未建立：我们旨在开发一种基于 ADCP 的特征来改善 GC 的预后预测：材料和方法：对表现出差异表达的抗体依赖性细胞吞噬基因进行表征，然后构建和验证基于 ADCP 的特征。探讨了基于 ADCP 的特征基因与 TME 之间的潜在关联，并研究了特征基因的特征。最后，根据基于 ADCP 的特征基因建立了预测性提名图：结果：确定了四个与 ADCP 相关的基因，即 MKNK2、VCAN、LRAT 和 GNGB，从而构建了基于 ADCP 的特征，ADCP 高分预示着 GC 患者的不良预后（P < 0.05）。基于 ADCP 的特征与免疫细胞、免疫检查点和免疫信号通路密切相关（p < 0.05）。与 ADCP 得分低的胃癌患者相比，ADCP 得分高的胃癌患者从免疫疗法中获益较少。通过构建包括年龄、分期和基于ADCP特征的风险评分的提名图，可以预测1年、3年和5年的生存概率，曲线下面积（AUC）分别为0.669、0.675和0.685：基于ADCP的特征可作为GC患者预后预测和个性化治疗的新选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Clinical and Experimental Medicine MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

3.70

自引率

4.80%

发文量

153

审稿时长

6-12 weeks

期刊介绍： Advances in Clinical and Experimental Medicine has been published by the Wroclaw Medical University since 1992. Establishing the medical journal was the idea of Prof. Bogumił Halawa, Chair of the Department of Cardiology, and was fully supported by the Rector of Wroclaw Medical University, Prof. Zbigniew Knapik. Prof. Halawa was also the first editor-in-chief, between 1992-1997. The journal, then entitled "Postępy Medycyny Klinicznej i Doświadczalnej", appeared quarterly. Prof. Leszek Paradowski was editor-in-chief from 1997-1999. In 1998 he initiated alterations in the profile and cover design of the journal which were accepted by the Editorial Board. The title was changed to Advances in Clinical and Experimental Medicine. Articles in English were welcomed. A number of outstanding representatives of medical science from Poland and abroad were invited to participate in the newly established International Editorial Staff. Prof. Antonina Harłozińska-Szmyrka was editor-in-chief in years 2000-2005, in years 2006-2007 once again prof. Leszek Paradowski and prof. Maria Podolak-Dawidziak was editor-in-chief in years 2008-2016. Since 2017 the editor-in chief is prof. Maciej Bagłaj. Since July 2005, original papers have been published only in English. Case reports are no longer accepted. The manuscripts are reviewed by two independent reviewers and a statistical reviewer, and English texts are proofread by a native speaker. The journal has been indexed in several databases: Scopus, Ulrich’sTM International Periodicals Directory, Index Copernicus and since 2007 in Thomson Reuters databases: Science Citation Index Expanded i Journal Citation Reports/Science Edition. In 2010 the journal obtained Impact Factor which is now 1.179 pts. Articles published in the journal are worth 15 points among Polish journals according to the Polish Committee for Scientific Research and 169.43 points according to the Index Copernicus. Since November 7, 2012, Advances in Clinical and Experimental Medicine has been indexed and included in National Library of Medicine’s MEDLINE database. English abstracts printed in the journal are included and searchable using PubMed http://www.ncbi.nlm.nih.gov/pubmed.